Introduction

When about 50 years ago Wolf1 noticed that some tiny and highly abundant objects present in human blood plasma contribute to clotting events, it seemed that there is something beyond clotting factors that may support platelets / thrombocytes in their aggregation and formation of a thrombus. This coagulant particulate material released from platelets (referred to as “platelet dust”) was produced in considerably larger amounts than required for thrombin generation. It was detected not only in plasma but also in serum, and its presence seemed to be associated with the platelet-like activity of the serum.1 The platelet activation leads to secretion of granules containing the procoagulant material and proteins involved in cytoskeletal arrangement, synaptic transportation, and secretion from their internal space.2 The processes of the formation and secretion of platelet “particles” are analogous to the processes occurring in other cells, including endothelial cells. They result in the formation of 2 types of membrane vesicles: bigger ones shed from the surface and named microvesicles (ectosomes) of 100 nm to 1 µm in diameter, and exosomes, measuring 40 nm to 100 nm in diameter. The latter are similar in size to the internal vesicles in multivesicular bodies (MVBs) and α-granules,3,4 and can be compared to endothelial vesiculation (Figure 1). Currently, the topic of extracellular vesicles (EVs) and their involvement in disease promotion and progression is gaining important insight in diagnostics and treatment.5 In this review, we focus on specific EV characteristics, still not intensively investigated, which contribute to the biological activity of EVs, that is, composition of the EV surface called a corona, and its charge.

Figure 1. Biogenesis and main characteristics of endothelial extracellular vesicles. Endothelial exocytosis occurs within minutes of stimulation. Exosomes are formed within inner membrane budding of the matured multivesicular bodies (MVB), and they are secreted during exocytosis. The hallmark proteins for exosomes are present on their surface (membrane organizers–tetraspanins, intercellular adhesion molecule 1 [ICAM-1] or receptors–integrins) or can be localized inside (flotillin 1, tumor susceptibility gene 101 protein [TSG101], cytoskeletal proteins–actin). Microvesicles, also called ectosomes, are created by direct budding of the plasma membrane and they are released into the extracellular space. As their biological origin and activity are associated with the extracellular space, they are additionally equipped with surface receptors (urokinase plasminogen activator surface receptor) and enzymes (eg, metalloproteinases [MMPs]).6 In this scheme, a commonly produced endothelial secretome protein, such as von Willebrand factor (vWF) is represented as a separate pathway.

Abbreviations: IL-8, interleukin 8; miRNA, micro-RNA; ncRNA, noncoding RNA

The biological activity of EVs depends on their cargo and their biological availability and biostability. The estimated blood plasma concentration of EVs in healthy individuals is between 108 and 1014 EVs/ml. Such discrepancies, more than 6 orders of magnitude, depend mainly on the isolation protocol and possible contamination by other colloidal particles present in the plasma, such as lipoproteins and large protein aggregates.6 In total platelet poor plasma, the average platelet microvesicle (PMV) content has been estimated at 109 to 1010 EVs/ml in patients on antiplatelet drugs and healthy individuals. PMV abundance depends mainly on the plasma purity and preanalytical handling.7-11 Assuming that one-third of the plasma EVs is of platelet origin, the number of the plasma EVs can be approximately 1010 EVs/ml.6 The average plasma residence time of intravenously delivered EVs ranges from 30 to 80 minutes and it is mainly regulated by the phagocyting activity of the mononuclear phagocyte system and by continuous turnover of EVs secreted by cells.12,13 Phagocytosis is one of the proposed mechanisms of EV internalization.14,15 Alternatively, EVs can be internalized by target cells in a variety of endocytic pathways (eg, clathrin-dependent endocytosis16 and clathrin-independent pathways, such as macropinocytosis,14 lipid raft-mediated internalization, or caveole-mediated uptake).14,17-19

What do extracellular vesicles contain?

The term EVs is used to refer to all membrane vesicles constituting a population of very diverse vesicular structures of different size and molecular content3,4,20 (Figure 2). Their molecular cargo has been intensively investigated and gathered in the biggest and manually curated compendia of molecular data for protein, lipid, and RNA, known as Vesiclepedia or ExoCarta21-23 or extracellular vesicle–associated DNA database (EV-ADD).24 Both populations of EVs (ectosomes and exosomes) contain or carry specific proteins, which can be considered potential biomarkers.25-27 For the endothelial cells, the most pathognomonic proteins are urokinase plasminogen activator surface receptor (uPAR),28,29 von Willebrand factor (vWF),30 heat shock proteins,31 and metalloproteinases.32,33

Figure 2. Exemplary microscopic representations of endothelial extracellular vesicles (EVs) showing their diversity and localization

Transmission electron microscopy reveals typical granular content of ectosomes released from human umbilical endothelial cells (HUVECs) of a diameter above 100 nm (A); exosomes are much smaller, and their cargo is more homogenous (B). Both structures are surrounded with a bilayer membrane. Below, endothelial cells produce an abundance of intracellular vesicles, most of which are Weibel-Palade bodies (green fluorescence) (C). EVs produced by the endothelium can also be internalized by cells located even at a distant site, here HUVECs captured external EVs which are red-labelled by a lipophilic dye and distributed within a target cell (D).

Another molecular hallmark of EVs is microRNA (miRNA), specific, noncoding short RNA molecules.34,35 For years, EV miRNAs have been considered as a way of cell-to-cell communication. Recently, stoichiometric studies of miRNAs and exosomes have showed that most individual exosomes do not carry biologically significant amounts of miRNAs and they are unlikely to function as vehicles for miRNA-based communication.36,37 Currently, EVs are rather considered a system for removing waste from the cells, which seems to be a good alternative to traditional laboratory biomarkers,38-40 or as vehicles for drug delivery systems for further clinical use.41,42

Molecular composition of EVs differs markedly also in terms of carbohydrates (glycans) attached to the surface proteins and forming a hydrophobic sugar overcoat (Figure 3). The presence and structure of glycans play a crucial role in cellular life and functioning of glycoproteins, for example, in cell-cell recognition, pharmacokinetics, physical stability, and immunogenicity. Glycans attached to proteins exert various important biological functions, such as: 1) targeting recognition, 2) modulating protein activity, or 3) stabilizing protein folding. Changes in the glycoproteome probably contribute to the age-related functional decline of the cardiovascular system as well as the heart and the aorta performance.43,44 Glycans covering the surface of EVs form a corona that has been recognized as a crucial mediator of EV functions.45,46 Glycomic profile of melanoma-derived ectosomes showed important correlation with melanoma malignancy.47 Differences in the surface glycosylation pattern, particularly in N-acetylglucosamine, mannose, and fucose-binding lectins result in facilitated EV-cell interactions and functional activation of endothelial cells.48 Glycans are key players in the regulation of EV uptake, through charge-based effects or direct glycan recognition by targeting receptors.49

Figure 3. Schematic representation of specific glycans enriched to extracellular vesicles (EVs). The surface of EVs has a complex glycosylation pattern, which has been studied to characterize and purify subpopulations of EVs, and it has also been shown that its manipulation increases EV delivery into cells.50

The importance of protein glycosylation for the biotechnology industry is highlighted by the fact that approximately 70% of therapeutic proteins, approved or in (pre-)clinical studies, are glycoproteins.

New feature of extracellular vesicles: a corona charge

Modification of surface N-glycans increases EV uptake and reduces EV charge, expressed as the zeta potential (ZP), from negative toward neutral. The other contributors to the surface charge are phospholipids, the most common of which is a negatively charged phosphate group (PO43−). This group, when covalently bound to the lipid glycerol moiety of a 2-chain fatty acid, forms the main group of charged fatty acids. Formation of EVs is very closely associated with the exposure of a membrane phospholipid phosphatidylserine (PS). Under normal conditions, PS is usually present in the inner membrane leaflet, but during EV secretion PS is transferred to the outer membrane leaflet.51 PS is composed of a negatively charged phosphate group attached to the serine at the hydroxyl end.

ZP is the measure that indicates the accumulation of negatively charged phospholipids in the inner membrane leaflet. Such accumulation of ions generates the ZP with an effective range of approximately 1 nm (Figure 4). Positively charged ions are attracted to the anionic surface, which is especially noticeable at the inner leaflet of the plasma membrane.

Figure 4. Schematic representation of electric charge distribution across the extracellular vesicle membrane and corona

ZP is the electrostatic potential present at the boundary between the diffuse layer and the compact layer (also known as the raft layer) of a colloid system, in the case of EVs, it is an EV suspension in a body fluid. This potential is related to the surface charge of the EVs and is used as an indicator of their stability and ability to form aggregates. The more negative the ZP, the weaker the forces attaching EVs together, and the stronger the EV affinity to positive or less negative surfaces. The cell surface charge varies between positive and negative electric state, and it depends on the balance between negatively and positively charged molecules. In physiological conditions, the surface charge of endothelial cells is less negative,52 and it changes toward higher values in pathological conditions or during cancerogenesis.53-55

ZP as an indicator of colloidal stability of dispersed particles is influenced by the charge of a colloid surface. ZP is one of the useful measures to characterize colloidal stability, including EV aggregation and their electrophoretic mobility.56 Biological membranes (including EVs) bear negatively charged glycoproteins and glycolipids forming a complex corona with the surrounding medium and regulating biological properties, such as adhesiveness and internalization.57,58 The charge of the EV corona depends on different factors that control the interactions between the particle surface and the medium, such as pH and ionic strength of the medium56 (Figure 4).

As shown in Table 1, values of EV ZP differ surprisingly, ranging from –20 to –10 mV for EVs isolated from macrophages, astrocytes, and neurons57 or from –40 to –30 mV for EVs isolated from cancer cells or erythrocytes.54,58 These variations in ZP have not been explored yet, and may result from diverse separation methods, contamination of EVs with different colloids including lipoproteins, as well as external conditions, such as low pH, high ionic strength, or valency of surface cations.29,30

Table 1. Exemplary zeta potential measures of extracellular vesicles derived from human cells

Origin

EV isolation methodology

EV zeta potential

Adipose-derived stem cells

300 g, 10 min

2000 g, 10 min

10 000 g, 30 min

100 000 g, 70 min

−10.8 ± 0.65 mV59

Human serum

TEIR

ExoQuick

miRCURY

Ultracentrifugation (20 000 g, 30 min; 110 000 g, 70 min)

From –9.80 mV to –21.1 mV60

Bone-marrow MSCs

300 g, 5 min

16 500 g, 40 min

Filtration, 0.2 µm

120 000 g, 70 min

−30 ± 1.13 mV61

HLSC culture media

Human serum and saliva

3000 g, 20 min

Filtration, 0.22 µm

3000 g, 20 min

10 000 g, 20 min

100 000 g, 60 min

HLSC culture medium –13.80 mV

Human serum –7.825 mV

Saliva –8.54 mV62

Glioblastoma cells

Exospin exosome purification kit

Empty exosome

−22.18 ± 8.73 mV

Incubation at 37 °C

−18.22 ± 1.23 mV

Sonication, −22.46 ± 0.63 mV63

Colon cancer HCT116 cell line and ASCs

3000 g, 30 min

13 000 g, 70 min

Sample concentration using an Amicon Ultra-15 Centrifugal Filter Devices (100 kDa, Millipore, Merck KGaA, Darmstadt, Germany)

120 000 g, 70 min

Filtration, 0.22 µm

TEx –9.20 ± 0.41 mV

AEx –7.22 ± 0.60 mV64

Lung cancer cells

750 g, 15 min

2000 g, 20 min

Filtration, 0.45 µm

10 000 g, 45 min

Filtration, 0.22 µm

100 000 g, 90 min

−14.4 ±3.3 mV at RT for exosomes diluted in PBS with trehalose

−11.8 ±1.5 mV at RT for exosomes diluted in PBS with DMSO65

Human NB cell lines HTLA-230, IMR-32, SH-SY5Y, and GI-LI-N

300 g, 10 min

10 000 g, 30 min

Filtration, 0.22 µm

Filtration, 0.1 µm

100 000 g, 75 min

Washing in PBS

2 × ultracentrifugation 100 000 g, 75 min

HTLA-230 −12.1 ±0.17 mV

IMR-32 −14.8 ±1.55 mV

SH-SY5Y −13.2 ±1.1 mV

GI-LI-N −12 ±0.15 mV66

Human umbilical cord–derived mesenchymal stromal cells

3200 g, 30 min

Filtration, 0.2 µm

Sample concentration using an Amicon Ultra-15 filter unit with Ultracel-100 membrane (MWCO = 100 kDa, Merck Millipore, Cat. No. UFC910024)

SEC column

From −7.73 ±3.76 mV to −12.4 ±2.5 mV67

Human urine–derived stem cells

Centrifugation using an Amicon Ultra15 Centrifugal Filter Tube (10 kDa; Millipore)

ExoQuick-TC Solution (System Biosciences, Palo Alto, California, United States)

1500 g, 30 min

−2.02 ±0.03 mV68

Red blood cells

1500 g, 10 min

3000 g, 15 min

25 000 g, 60 min

~200 g, 120 min

−36.4 ±7.8 mV69

Raw bovine milk

13 000 g, 30 min

90 000 g, 60 min

180 000 g, 120 min

Filtration, 0.2 µm

Exo-PAC −28.28 ±1.8 mV

Exo-5-FU −27 ±1.6 mV; plain exosomes −23 ±1.2 mV70

Human serum

Total exosome isolation from serum (Invitrogen by Thermo Fisher Scientific, Vilnius, Lithuania)

Serum small EVs (sEVs) from RB individuals −11.04 ±0.4 mV

Serum small EVs (sEVs) from non-RB individuals –12.72 ±1.7 mV71

Murine cardiac fibroblasts (CF) and CF-derived iPS

3000 g, 10 min

Filtration, 0.2 µm

precipitation overnight in PEG buffer at 4 ˚C

1500 g, 30 min

CF exosomes −14.22mV

iPS exosomes −15.44 mV72

Human immortalized microvascular endothelial cell line (TIME)

2000 g, 30 min

18 000 g, 30 min

150 000 g, 90 min

Ectosomes –9.3 ±0.7 mV

Exosomes –11.35 ±1.9 mV22

Abbreviations: AEx, adipose stem cells–derived exosomes; ASCs, adipose stem cells; DMSO, dimethyl sulfoxide; Exo-5-FU, 5-fluorouracil-loaded exosomes; Exo-PAC; paclitaxel-loaded exosomes; HLSC, adult human liver stem cells; iPS, induced pluripotent stem cells; MLC, mixed lymphocyte culture; MWCO, molecular weight cutoff; NB, neuroblastoma; PBS, phosphate-buffered saline; RB, retinoblastoma; SEC, size exclusion chromatograhy; TEIR, Total Exosome Isolation Reagent for serum; TEx, tumor cell-derived exosomes

Concluding remarks

EVs are very attractive research objects as potential biomarkers of various pathologies due to their specific cargo and abundance in the cellular environment. As they have different cellular origin, they also differ in their metabolic competencies, and carry a variety of bioactive molecules, such as miRNAs, proteins, and lipids. However, their biodistribution and availability are also important and still underestimated features. For their further use in clinical practice as potential drug carriers, their biodistribution and uptake by target cells should be considered. To better understand the mechanisms of cell internalization, most attention should be given to the EV surface properties related to the EV corona and surface charge, characterized by glycosylation and ZP.